Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review)

Kausar,Mohd Adnan; Anwar,Sadaf; El-Horany,Hemat El-Sayed; Khan,Farida Habib; Tyagi,Neetu; Najm,Mohammad Zeeshan; Sadaf,; Eisa,Alaa Abdulaziz; Dhara,Chandrajeet; Gantayat,Saumyatika

doi:10.3892/ijo.2023.5578

Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review)

Authors:
- Mohd Adnan Kausar
- Sadaf Anwar
- Hemat El-Sayed El-Horany
- Farida Habib Khan
- Neetu Tyagi
- Mohammad Zeeshan Najm
- Sadaf
- Alaa Abdulaziz Eisa
- Chandrajeet Dhara
- Saumyatika Gantayat
View Affiliations

Affiliations: Department of Biochemistry, College of Medicine, University of Ha'il, Ha'il 81411, Saudi Arabia, Medical and Diagnostic Research Centre, University of Ha'il, Hail 55473, Saudi Arabia, Bone Biology Laboratory, Department of Physiology, School of Medicine, University of Louisville, Louisville, KY, 40202, USA, School of Biosciences, Apeejay Stya University, Sohna, Gurugram 122003, Haryana, Department of Biotechnology, Jamia Millia Islamia, Okhla, New Delhi 110025, India, Department of Medical Laboratories Technology, College of Applied Medical Sciences, Taibah University, Medina 30002, Saudi Arabia
Published online on: October 10, 2023 https://doi.org/10.3892/ijo.2023.5578
Article Number: 130
Copyright: © Kausar et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer is the primary and one of the most prominent causes of the rising global mortality rate, accounting for nearly 10 million deaths annually. Specific methods have been devised to cure cancerous tumours. Effective therapeutic approaches must be developed, both at the cellular and genetic level. Immunotherapy offers promising results by providing sustained remission to patients with refractory malignancies. Genetically modified T‑lymphocytic cells have emerged as a novel therapeutic approach for the treatment of solid tumours, haematological malignancies, and relapsed/refractory B‑lymphocyte malignancies as a result of recent clinical trial findings; the treatment is referred to as chimeric antigen receptor T‑cell therapy (CAR T‑cell therapy). Leukapheresis is used to remove T‑lymphocytes from the leukocytes, and CARs are created through genetic engineering. Without the aid of a major histocompatibility complex, these genetically modified receptors lyse malignant tissues by interacting directly with the carcinogen. Additionally, the outcomes of preclinical and clinical studies reveal that CAR T‑cell therapy has proven to be a potential therapeutic contender against metastatic breast cancer (BCa), triple‑negative, and HER 2+ve BCa. Nevertheless, unique toxicities, including (cytokine release syndrome, on/off‑target tumour recognition, neurotoxicities, anaphylaxis, antigen escape in BCa, and the immunosuppressive tumour microenvironment in solid tumours, negatively impact the mechanism of action of these receptors. In this review, the potential of CAR T‑cell immunotherapy and its method of destroying tumour cells is explored using data from preclinical and clinical trials, as well as providing an update on the approaches used to reduce toxicities, which may improve or broaden the effectiveness of the therapies used in BCa.

1. Introduction

The complex and diverse group of disorders collectively referred to as malignant cancer is characterised by the dissemination and proliferation of aberrant cells in the body. Physiologically normal cells undergo a systematic process of growth, division and apoptosis, or programmed cell death, to reach senescence. In contrast, cancer cells proliferate aggressively, giving rise to malignant tumours that can invade and destroy adjacent tissues and organs by spreading through the bloodstream or lymphatic system (1). Numerous variables can contribute to the development of malignancies, including genetic alterations, exposure to carcinogens such as tobacco smoke or UV radiation, and dietary and lifestyle choices (2). While various treatment methods, including surgery, radiation therapy, and chemotherapy, are available for different types of malignancies, the primary challenge lies in revolutionising the diagnosis and prognosis of cancer at both the cellular and genetic levels (3). In the late 19th century, surgeon William Coley observed that certain cancer patients suffering from bacterial infections experienced spontaneous cancer remission. This observation led Coley to inject heat-killed Streptococcus pyogenes and S. marcescens into cancer patients to boost their immune systems. Although the results were mixed, his work laid the foundation for modern immunotherapy (4). In the 1890s, Paul Ehrlich delved deeper into the concept that the immune system is capable of detecting and eliminating malignant cells. He laid the groundwork for active and passive immunity, a concept he later referred to as 'cancer immunity' (5). Research at the National Cancer Institute by Rosenberg (6) explored the efficacy of interleukin-2 (IL-2) in stimulating cell growth and combating cancerous cells. The development and advances of cancer immunotherapy gained notable momentum following the development of the first monoclonal antibody (mAb), rituximab, for treating non-Hodgkin lymphoma (NHL) in 1997. Monoclonal antibodies are one of the three adoptive cell transfer (ACT) therapies used for diagnosing malignancies and for prognostic evaluation (7,8). For example, subcutaneous FBL3 lymphomas were lysed by infusing IL-2 intravenously. Studies also investigated the use of genetically altered T-lymphocytes to target tumour antigens (6,9). After a decade of studies and trials, Eshhar et al (10) developed a genetically engineered therapy using chimeric proteins that could recognize and target specific malignant antigens expressed on T-cells. This therapy is known as chimeric antigen receptor (CAR) T-cell therapy. The process involves leukapheresis, a procedure used to isolate T-lymphocytes from a patient's leukocytes, followed by the infusion of genetically altered CARs into the patient's circulatory system. Over a decade of successful innovations, CARs have evolved, incorporating different domains and co-stimulatory, elements that enhance their ability to bind to cancerous cells and tissues, facilitating the lysis of cancerous cells. This evolution has led to CAR T-cell therapy becoming a novel therapeutic option for conditions such as multiple myeloma (MM), B-cell acute lymphoblastic leukaemia (B-ALL), and other aggressive tumours (11,12). Recent achievements in CAR T-cell therapy, driven by molecular and immunological insights, provide the foundation for its advancement as a more efficient and precise therapeutic approach. These advances are further discussed in the following sections.

2. Requirements for CAR T-cell development

The demand for T-cell receptors (TCRs) in curing metastatic melanoma, was unparalleled due to their remarkable efficacy. However, their success as a therapeutic option was accompanied by a series of adverse side effects including off-target toxicity, cardiac toxicity, neurological toxicities, and various other life-threatening complications, which led to the exploration of neoantigens as a potentially safer approach (13,14). The introduction of CAR T-cell therapy ushered in cutting-edge technologies across various disciplines, including immunogenetics, molecular genetics, and oncogenetics. This approach involves the use of protein receptors known as chimeric T-lymphocytic receptors, which have evolved to enable T-cells to precisely target specific antigens. Their ability to combine components for T-cell activation and antigen binding justifies the term 'chimeric' being applied to them (15,16). The basic structural composition of CAR includes the extracellular domain (also referred to as the target and spacer motif), the transmembrane motif, and a signalling motif. Each of these domains significantly influences anti-carcinogenic effectiveness and CAR T-cell production (15).

3. Characterisation of the CAR domains

Ligand-binding domain

The targeting domain, also known as the ligand-binding domain, primarily consists of a fragment called single-chain variable fragment (ScFv) (Fig. 1), produced from non-human sequences found in mABs capable of eliciting immunogenic responses. Theoretically, ScFv can recognise a wide range of surface antigens expressed on target cells (such as HER2, PSMA, and CD19) (15,17). In addition, other domains incorporate nanobodies and receptor-cognate ligands, such as NKG2D, IL-2R, IL-7R, T1E, and PD-1, to target multiple ligands (18,19). Certain cases have reported potent anti-tumour activity with ScFv, which, however, can lead to neurotoxicity and could potentially be resolved through the optimisation of ligand-binding affinities (20).

Figure 1

Chimeric antigen receptors are composed of a signalling motif, a transmembrane motif, a spacer motif, and a ligand-binding motif.

Spacer domain

To provide flexibility to the recognition sites of CAR T-cells, the spacer domain connects ScFv to the transmembrane domain. This function of the spacer domain is to determine the impact based on its length (15). For larger tumour sizes, the binding of epitopes with a spacer domain of a specific length becomes necessary. However, off-target binding can compromise the safety and effectiveness of a therapy (21,22). For example, the interaction of FcRs with the IgG1 Fc spacer domain on rodent macrophages can lead to CAR-induced cell death. To address this issue, Hudecek et al (22) proposed the deletion of the Fc spacer CH2 domain, a critical component of chimeric Fc-FcR interactions. Based on the results of clinical studies, the US Food and Drug Administration (FDA) has approved certain non-IgG-based spacer domains, such as CD8 and CD28, which are widely used in therapy. Spacers also play a role in quantifying and purifying CAR-positive subsets after engineering.

Transmembrane domain

The transmembrane domain serves as a linker, acting as a pivot point for transmitting ligands and recognition signals to the signalling domain. The TCR-CD3 complex's domains play a crucial part in organising the assembly. Cysteine residues in the transmembrane domain of CD3 are made possible by the dimerization of CD3ζ in the first generation of chimeric antigen T-lymphocytes. This domain is exposed to hydrophobic conditions containing non-polar amino acids as it is an integral part of the basic structure of the genetically modified T-lymphocyte receptor. In the current context, designs of this domain are borrowed from CD4 and CD28, which are relatively independent of the TCR complex and ensure the binding of the independent TCR to the target. According to a review study by Cheng Zhang et al (23) and Sterner et al (24), the most widely accepted and used transmembrane domain is CD28 or CD8α, which is chosen to optimise receptor expression and stability.

Signalling domain

The CAR T-cell therapy can only be partially explained without discussing the signalling domain. The signalling or co-stimulatory domains were engineered in the 1990s and include a CD3ζ domain and a tyrosine-based immunoreceptor (ITAM). ITAMs are present on the TCR-CD3 complex and serve as crucial phosphorylation sites to recruit ZAP70, which plays a critical role in signalling cascades (17). The importance of signalling domains has been discussed in the previous section, with CD28 and 4-1BB as recognised co-stimulatory domains for various B-cell malignancies in the second generation of CARs; this is further elaborated elsewhere (24).

4. Generations of CARs

First generation

The CD3ζ chain serves as the primary stimulatory domain in the initial CAR T-cell therapy paradigm from the 1990s. These engineered receptors were widely accepted due to the presence of CD3ζ and ITAMs (Fig. 2) (25,26). Specific drugs for this generation entered clinical trials for the management of leukaemia, ovarian cancer, and neuroblastoma (NB) following successful preclinical results. B-cell lymphoma (BCL) patients received infusions of CD20-CD3ζ CAR T-cells, and several neuroblastoma patients received treatment with ScFv-CD3ζ CAR T-cells. The genetically altered signalling receptors, now known as CARs, were initially referred to as the 'T body approach' model (27,28).

Figure 2

There are five generations of CAR T-cells. CAR T-cell products made by Kymriah® and Yescarta®, which were approved by the FDA in 2017 are the most prevalent examples of CAR T-based therapies. (A) An intracellular CD3 ITAM, a transmembrane domain, and ScFv are all present in first-generation CARs. (B) Second-generation CARs include auxiliary coordinating domains such as CD28, CD137, and 4-1BB. (C) Third-generation CARs incorporate the addition of two coordinating domains, such as CD3ζ-CD28-OX40 and CD3ζ-CD28-4-1BB, resulting in an increased cytotoxic effect on carcinogenic cells. (D) In fourth-generation CARs, TRUCKs are inserted as the co-stimulatory domain to enhance IL12 production. (E) In fifth-generation CARs, within CD28 and ITAMs, the IL2Rβ-derived JAK-STAT activation domain is present. ITAM, immunoreceptor tyrosine-based activation motif; ScFv, single-chain variable fragment; CAR, chimeric antigen receptor; TRUCK, T-cells redirected for universal cytokine killing; FDA, Federal Drug Administration.

Second generation

The success of the first generation of studies paved the way for a second-generation therapy. The two co-stimulatory domains that have received FDA approval are CD28 and 4-1BB, showing substantial therapeutic benefits in several cancers including chronic lymphoblastic leukaemia (CLL), B-ALL, and multiple myeloma (Fig. 2) (29). Furthermore, a phosphoproteomic mass spectroscopy study demonstrated that CARs with CD28 domains phosphorylate more rapidly and intensely than those with 4-1BB domains. In summary, CD28-based chimeric receptors enhance effector T-cell proliferation responses, whereas 4-1BB-based CARs promote T-cell accumulation (28,29).

Third generation

Enhanced anti-carcinogenic efficacy is achieved by incorporating two signalling domains. Third-generation therapies, such as CD3-CD28-OX40 and CD3-CD28-4-1BB, boost cytokine production and activation signals to promote prolonged proliferation (Fig. 2) (30). Preclinical results for anti-PSMA and anti-mesothelin CD28-4-1BB-CD3ζ CARs have shown increased tumour eradication and persistence abilities compared with the second-generation therapies. These two motifs have been evaluated against several targets including CD19, PSMA, GD2, and mesothelin (31-34).

The superiority of third-generation therapies over second-generation therapies remain a subject of debate. For example, CD28-4-1BB-based CARs demonstrate better preclinical results in mouse xenografts of pancreatic cancer in the third generation. However, second-generation therapies have still outperformed the subsequent generations in terms of their anti-carcinogenic potency. Third-generation therapies exhibit improved in vitro secretion of cytokines such as IL2 and TNFα with anti-GD2 CARs consisting of the CD28-OX40-CD3ζ domain. This domain also shows enhanced proliferation and expansion compared with the second- and first-generation therapies (35,36).

Fourth generation

All previous generations of CAR T-cell therapies exhibit a lack of anti-carcinogenic activity against solid tumours due to the inhospitable microenvironment of solid tumours resulting in heterogeneity and deterioration. The fourth-generation CAR T-cell therapy is also known as T-cells redirected for universal cytokine killing (TRUCK) or 'armoured CARs' (37,38). These armoured chimeric receptors can express cytokines and chemokine receptors such as IL12 to enhance T-cell penetration and protect T-lymphocytes from the oxidative stress microenvironment to enhance infiltration (Fig. 2) (39). An illustrative example involves using antigen-negative cancer cell regulators as a target for antagonistic antibodies such as CTLA-4 and PD-1 demonstrating that blocking PD-1 improves the regulation of HER-2 redirected CAR T-cells leading to an enhanced immune response in HER-2 competent transgenic mice (40).

Fifth generation

Recently, membrane-based receptors have been developed, incorporating an IL2Rβ domain inserted between the co-stimulatory domains CD247 and CD28 to trigger cytokine signalling (Fig. 2). The presence of the YXXQ STAT3 binding motif in the IL2Rβ domain facilitates the induction of CAR T-cells and may activate the JAK-STAT pathway to promote cell proliferation. This generation of CART-cells has shown better persistence in leukaemia (41,42).

5. Mechanism of lysing the tumour cells

CARs serve as a membrane bridge with their receptors spanning both the cell's intracellular and extracellular matrix. The portion protruding from the cell surface typically consists of synthetic antibodies acting as the basic antigen recognition motif. The choice of domains used determines the receptor's ability to detect or bind to tumour cell antigens. Each CAR's internal region, which includes the T-lymphocyte trigger unit and 'co-stimulatory' domains, plays a crucial signalling role. These domains are responsible for transmitting signals within the cell following the interaction between the receptor and antigens. The specific domains used can impact the overall function of the cells. Unlike endogenous TCRs, CARs can recognise unprocessed antigens, regardless of how major histocompatibility antigens are presented. CARs can bind to various targets, including protein-protein peptides, sugars, highly glycosylated proteins, and gangliosides, thus broadening the range of potential targets. While ScFv derived from antibodies are commonly used in the interaction between a CAR and its target, Fab fragments (Fab) acquired from libraries and natural ligands (also known as first-generation CARs) have also been used (43,44).

Leukapheresis, a procedure used to isolate T-cells from leukocytes, is the first step in the mechanism of action. In leukapheresis, leukocytes, T-cells, and other components are separated, following which, in vitro cloning is performed using viruses to develop a modified gene capable of encoding the chimeric receptors (44). The designed CARs recognise and bind to specific antigens or proteins found on the surface of malignant cells (45). The in vitro-engineered T-cells are then expanded to produce tens of thousands of copies. This process may take several weeks and involves the use of cytokines and other growth factors to stimulate T-cell proliferation. Following this, the engineered receptors are introduced into the patient's bloodstream.

Once in the circulatory and lymphatic systems, CAR T-cells come into contact with antigen-presenting cancerous cells. When a CAR encounters the cancer cell expressing the target antigen, it initiates intracellular signalling processes that activate CAR T-cells, leading to an increase in cytokine production. This activation allows CAR T-cells to directly attack the tumour cells through cytotoxicity. CAR T-cells release cytotoxic chemicals, such as perforin and granzymes, which induce apoptosis (programmed cell death) in the cancer cells (Fig. 3) (45). Additionally, CAR T-cells can stimulate other immune cells, such as natural killer (NK) cells and tissue macrophages, which contribute to immune responses aimed at destroying cancer cells or tissues. In certain rare cases, these augmented T-cells can persist in the patient's immune system providing ongoing protection against cancer recurrence (46).

Figure 3

CAR T-cell mode of action for identifying and binding with tumour antigens and releasing cytokines (perforins and granzymes) resulting in the lysis of carcinogenic cells/tissues.

6. Preclinical experiments on mouse models

Preclinical trials involving xenograft humanised mouse models to investigate tumour progression have enabled researchers to study the tumour microenvironment (TME), which includes components such as blood vessels, lymphocytes, fibroblasts, and the extracellular matrix (ECM). This research has led to the development of humanised patient-derived xenograft (hu-PDX) mouse models designed to preserve genetic profiles and drug responses. The hu-PDX mouse model closely replicates the TME found in humans, with cytokines and chemokines playing a critical role in regulating angiogenesis, metastasis, and immune responses (47,48). Humanised mouse models have been employed in ACT T-lymphocytic therapy to enhance the recognition and elimination of cancer cells. For example, the maturation of transgenic Wilm's tumour (WT-1-specific TCRs in HLA-I transgenic NSG mice transplanted with haematopoietic stem cells (HSCs) enhances cell proliferation capacity and triggers cytokine immune responses, which results in the amplification of anti-carcinogenic effects (49). The success of ACT T-lymphocytic therapies in preclinical and clinical settings paved the way for CAR T-cell therapy in cancer treatment. The necessity to simulate human-originated tumours within an intact immune system has been recognized with the co-evolution of anti-tumour T-cells and the use of CAR T-receptors on humanised (HM) and genetically modified (GEMM) mouse models (50,51). In HM mouse models, experiments involving humanised NRG mice treated with gp350 CAR T-cells showed a reduction in Epstein-Barr virus (EBV) levels. This research has stimulated further investigation into the correlation between the spread of a virus and the incidence of cancer (52). Currently, CAR T-cell therapy has demonstrated significant efficacy in treating various haematological and B-cell malignancies without the restriction of major histocompatibility complex. Chimeric receptors have been engineered to target CD19 in the hu-BLT (bone marrow, liver, and thymus) mouse model, with positive responses observed against primary acute B-ALL (53). As therapies have advanced, the introduction of co-stimulatory motifs such as 4-1BB (CD28 and CD137) has shown promise in enhancing anti-neoplastic responses and cancer cell elimination in hu-SRC (SCID repopulating cell) mice (54). This review emphasises the efficacy of CAR T-cells in BCa treatment and sheds light on various preclinical studies aimed at better understanding their potential. The human epidermal growth factor receptor 2 (HER2 also known as ERBB2 belongs to the receptor tyrosine-protein kinase family (55). When triggered, downstream signalling pathways lead to gene overexpression and initiate tumour metastases. In BCa, 20-30% of the patient population exhibit HER2 amplification, highlighting its value as a target in BCa therapy. In preclinical studies, HER2 CAR T-cells resulted in the eradication of tumour cells, even in trastuzumab-resistant JIMT-1 xenografts, leading to improved survival rates in xenograft mice (56). Preclinical studies have targeted various BCa antigens such as FRα, epidermal growth factor receptor (EGFR), AXL, MUC1, c-Met, TEM8, and NKG2D, to optimise the efficacy of CAR T-cell therapy in both preclinical and clinical settings. The third generation of CAR T-cell therapy, which includes anti-EGFR antibodies in the ScFv region, has exhibited anti-carcinogenic responses in xenograft mouse models of triple-negative BCa (TNBC) cell lines (57). TNBC offers several potential cell targets, including MUC1, c-Met, AXL, NKG2D, integrin αvβ3, and ROR1, all of which have shown promising preclinical results in various in vitro and in vivo models of engineered CAR T cell therapy (58). For example, CAR T-cells based on the receptor tyrosine kinase AXL have demonstrated significant efficacy in regulating in vitro cytotoxicity in MDA-MB-231 xenograft mice for TNBC (59). Another surface receptor, integrin αvβ3, which plays a role in cell adhesion between epithelial cells and their microenvironment has been targeted using a second generation of chimeric T-lymphocytes in preclinical stages, leading to the release of cytokines such as IL2 and IFNγ (60). The tyrosine kinase receptor c-Met is also being targeted with engineered CAR T-receptors to induce cytolysis in TNBC cells and reduce tumour progression in TNBC xenografts with intact immune metabolism (61). NKG2D-CAR T-cell therapy has been used to target xenograft mouse models by inducing pro-inflammatory responses. In second-generation therapies, these engineered receptors, incorporating co-stimulatory motifs such as 4-1BB, have been shown to regulate anti-carcinogenic activity in vivo (62). Transmembrane proteins such as MUC1 are often overexpressed in TNBC cells in glycosylated form. Therefore, tMUC1-CAR T-cell receptors have been engineered to stimulate cytokines and chemokines to act on mutant alleles in xenograft mice in vitro (63). Aberrations in breast tissues contributing to TNBC can potentially be treated with tyrosine kinase-like orphan receptor 1 (ROR1)-CAR T-cells, which stimulate anti-carcinogenic responses in different in vitro models (64). Numerous other potential cellular targets for TNBC have been explored in preclinical studies, as demonstrated below (Table I).

Table I

T-lymphocytic CAR targets for TNBC.

Table I

T-lymphocytic CAR targets for TNBC.

CAR T-lymphocytic target	Pre-clinical outcomes in TNBC	(Refs.)
AXL	Reduces tumour progression in MDA-MB-231 xenograft mice, Showed in vitro cytotoxicity. The intrinsic regulation of IL7 cytokine enhances the anti-carcinogenic activities in vitro.	(59,65)
CD32A	Combination with cetuximab or panitumumab leads to the lysis of EGFR+ve MDA-MB-468 TNBC cells and the release of cytokines like IFNγ and TNFα.	(66)
EGFR	EGFR-derived receptors are responsible for the lysis of TNBC tissues in both in vitro and in vivo models.	(57)
FRα	In vitro lysis of TNBC cells and regression in an MDA-MB-231 xenograft model. Used as a potential biomarker for effective clinical efficacy.	(67)
GD2	Induces cytotoxicity in TNBC tissues of in vivo models.	(68)
ICAM-1	Acts as a mediator in in vivo TNBC tissues such as an MDA-MB-231 mouse model.	(69)
Integrin α_vβ₃	Overexpression of integrins in the pre-clinical stages helps target TNBC tissues with second generation-engineered receptors, which results in the release of cytokines such as IL2 and IFNγ.	(60)
Mesothelin	Acts as an effector in the PD-1 knockout mouse model of TNBC.	(70)
c-Met	Triggers cytolysis of triple negative carcinogenic breast tissues to reduce tumour progression in xenograft models with intact immune metabolism.	(61)
MUC1	Upregulated in TNBC cells in the glycosylated form regulates mutant alleles of xenograft mouse models in vitro.	(63)
NKG2D	In a xenograft mouse model, it induced proinflammatory responses to second generation therapies using co-stimulatory motifs 4-1BB to regulate the anti-carcinogenic activities in vivo.	(62)
ROR1	Induces anti-carcinogenic responses in different in vitro 3D culture models.	(64)
TEM8	Anti-carcinogenic responses in TNBC xenograft mouse models. Causes off-target toxicity in in vivo models.	(71,72)
TROP2	Upregulated in TNBC carcinogens. Associated with a poor prognosis due to its promoting effect on pro-carcinogenic signalling pathways. Targeting this results in the elimination of epithelial malignancies in in vitro models.	(73)

[i] AXL, tyrosine kinase receptor; CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor; FRα, folate receptor α; GD2, disialoganglioside GD2; ICAM-1, intracellular adhesion molecule-1; c-MET, mesenchymal-epithelial transition factor; MUC1, mucin 1 glycoprotein; NKG2D, natural killer group 2-member D; ROR1, receptor tyrosine kinase-like orphan receptor 1; TEM8, tumour endothelial marker 8; TROP2, trophoblast cell surface antigen 2.

7. Malignancy-specific CAR T-cell clinical trials and BC CAR T-cell clinical studies

Numerous clinical trials are currently underway to develop and advance CAR T-cell immunotherapy (Table II) to assess the effectiveness of this treatment approach for various malignancies. These trials primarily involve patients with B-NHL, B-ALL, CLL, and glioblastoma, as well as other solid tumours and relapsed/refractory malignancies. It would be a remarkable achievement if some of these trials meet the regulatory standards set by the US FDA.

Table II

Malignancy-specific CAR T-cell clinical trials.

Table II

Malignancy-specific CAR T-cell clinical trials.

NCT number	Malignancy	Phase	Target antigen	(Refs.)
NCT02208362	Glioblastoma	Phase 1	IL13Ra2	(74)
NCT03726515	Glioblastoma	Phase 1-completed	EGFRvIII	(75)
NCT03198546	LUSC	Phase 1	GPC3	(76)
NCT00902044	OS	Phase 1	HER-2	(77)
NCT01373047	LIHC	Phase 1-completed	CEA	(78)
NCT01897415	PAAD	Phase 1-completed	Mesothelin	(79)
NCT03323944	PAAD	Phase 1	Mesothelin	(80)
NCT03159819	STAD & PAAD	N/A	Claudin 18.2	(81)
NCT03393936	RCC	Phase 1/2	AXL	(82)
NCT03873805	CRPC	Phase 1	PSCA	(83)
NCT03089203	CRPC	Phase 1	PSMA	(84)
NCT04020575	BRCA	Phase 1	MUC1	(85)
NCT03585764	PCC	Phase 1	Folate receptor-α	(86)
NCT02498912	PCC	Phase 1	MUC16	(87)
NCT02792114	BRCA	Phase 1	Mesothelin	(88)
NCT02442297	CNS Tumour	Phase 1	HER2	(89)
NCT03696030	LM, BRCA, HER2+ve BRCA	Phase 1	HER2	(90)
NCT02414269	MPE, BRCA	Phase 1/2	Mesothelin	(91)
NCT01044069	B-ALL	Phase 1	CD19	(92)
NCT00466531	B-CLL	Phase 1/2	CD19	(93)
NCT00586391	BCL/CLL/ALL	Phase 1	CD19	(94)
NCT00608270	B-NHL	Phase 1	CD19	(95)
NCT02315612	B-NHL	Phase 1	CD22	(96)
NCT01722149	MPM	Phase 1-completed	FAP	(97)
NCT02311621	NB	Phase 1	CD171	(98)
NCT03274219	MM	Phase 1	BCMA	(99)
NCT00881920	CLL, BCL, MM	Phase 1	CD28	(100)
NCT03939026	r/r BCL, r/r FL	Phase 1	CD19	(101)
NCT03666000	r/r ALL, r/r NHL	Phase 1/2	CD19	(102)
NCT04035434	r/r NHL, r/r BCL	Phase 1	CD19	(103)
NCT03190278	r/r-AML	Phase 1	CD123	(104)
NCT04093596	r/r-MM	Phase 1	BCMA	(105)
NCT03692429	MCRC	Phase 1	NKG2D	(106)
NCT01044069	B-ALL	Phase 1	CD19	(92)
NCT01140373	CMPC	Phase 1	PSMA	(107)
NCT01822652	NB	Phase 1	GD2	(108)
NCT01953900	NB, OS	Phase 1	GD2	(109)
NCT02208362	r-Glioblastoma	Phase 1	CD19	(74)

[i] N/A, not applicable; LUSC, lung squamous cell carcinoma; OS, osteosarcoma; LIHC, liver hepatocellular carcinoma; PAAD, pancreatic adenocarcinoma; STAD, stomach adenocarcinoma; RCC, renal cell carcinoma; CRPC, castrate-resistant prostate cancer; PCC, peritoneal cell carcinoma; BRCA, breast cancer; LM, leptomeningeal metastases; MPE, malignant pleural effusion; B-ALL, B-cell acute lymphoblastic leukaemia; B-CLL, B-cell chronic lymphoblastic leukaemia; BCL, B-cell lymphoma; B-NHL, B-cell non-Hodgkin lymphoma; MPM, malignant pleural mesothelioma; NB, neuroblastoma; MM, multiple myeloma; FL, follicular lymphoma; r/r-, relapsed and refractory; AML, acute myeloid lymphoma; MCRC, metastatic colorectal cancer; CMPC, castrate metastatic prostate cancer; CNS, central nervous system.

Several clinical studies for administering chimeric antigen immunotherapy in BCa patients are presented in Table III.

Table III

Breast carcinoma CAR T-cell clinical studies.

8. FDA-approved therapies

Drugs for treating several refractory/relapsed B-lymphocyte malignancies, including diffuse large cell BCL (DLBCL), have been approved by the FDA in the United States. These approvals stem from promising preclinical studies on mouse models and impressive results from clinical trials. In 2018 FDA granted approval to CTL019 (tisagenlecleucel; NCT02228096; Fig. 4) for use in paediatric B-ALL patients who had relapsed or failed previous treatments. A single-arm, open-label, multi-central phase II research study is currently ongoing to evaluate CTL019's safety and efficacy in patients with r/r-B-ALL. This treatment has shown a high success rate, with CTL019 achieving a 3-month full remission rate of 83% and a 6-month survival rate of 89%. Additionally, the ZUMA-1 trial reported a total remission rate of 59% and an overall response rate of 82% (110,111). In 2019, following the completion of a phase II clinical study, KTE-C19 (NCT02348216; axicabtagene ciloleucel) received FDA authorisation as an orphan medication for the treatment of adults with r/r-DLBCL. After undergoing Yescarta therapy, the complete remission rate was 51% (112). In 2020, brexucabtagene autoleucel was approved for the treatment of certain patients with Mantle cell lymphoma (MCL) (NCT02601313). Furthermore, in October 2021, brexucabtagene autoleucel (Tecartus) received approval for the treatment of adult patients with r/r-B-cell precursor ALL. These trials were conducted under ZUMA-3 phase I/II (NCT02614066), evaluating CD19-targeted CAR T-cell therapy for adult r/r-B-ALL A phase I trial infused lisocabtagene maraleucel (NCT02631044) to assess the drug's safety and efficacy levels for patients with r/r-B-cell NHL. According to a 23-month trial, lisocabtagene maraleucel achieved an overall response rate (ORR) of 73% (113). In 2021, idecabtagene vicleucel was authorised by the US FDA for use in treating adult patients with r/r-multiple myeloma. An ongoing phase II trial [NCT03361748] for this drug showed ORR and CR rates of 72 and 28%, respectively with ~65% of patients remaining in CR for a full year. Finally, ciltacabtagene autoleucel was licensed for adult patients with r/r-multiple myeloma in February 2022 based on the findings of the phase II clinical study [NCT03548207]. The clinical study reported an ORR of 97.9%, a response time of 21.8 months, and a follow-up time of ~18 months. To identify the most precise medications for specific types of malignancies and further enhance treatment efficacy several clinical trials are currently underway, with the potential for future FDA approvals (Table II).

Figure 4

FDA-approved drugs for the CAR-T-cell therapy of different malignancies such as B-ALL, DLBCL, r/r-B-ALL, B-cell NHL, and r/r-MM in paediatric and adult patients. FDA, Federal Drug Administration; B-ALL, B-cell acute lymphoblastic leukaemia; DLBCL, diffuse large cell B-cell lymphoma, r/r-, relapsed/refractory; B-cell NHL, B-cell non-Hodgkin lymphoma; MM, multiple myeloma.

9. Contemporary advances in breast carcinoma CAR T cell therapy

In accordance with the intensity of their expression, tumour antigens are categorised into three groups: Cancer germline antigens, tumour-specific antigens (TSAs), and tumour-associated antigens (TAAs) (114). Cancer cells display TSAs on their surface with malignant cells being rich in TAAs such as HER2 and CD19 (115,116). Targeting TSAs can lead to side effects such as on-target/off-target toxicity as chimeric T-cells attack them (117). Inhibitors such as PARP, CDK4/6, AKT, and HER2, that affect various carcinogenesis pathways, including the cell cycle, metastasis, and angiogenesis, have been investigated as potential therapeutic targets for impeding BCa proliferation. To date, four PARP antagonists (olaparib, talazoparib, rucaparib, and niraparib) have undergone extensive clinical research. Olaparib, the first FDA-approved PARP inhibitor, targets the genetic activity of the TOPBP1 and WEE1 genes. Olaparib is administered both as combination therapy (alongside chemotherapy) and as a monotherapy, with common side effects including anaemia and neutropenia (NCT02000622, NCT01445418, NCT02734004, NCT02032823, and NCT02789332) (118,119). CDK4/6 plays a crucial role in facilitating tumour cell progression. FDA-approved CDK4/6 antagonists include palbociclib, abemaciclib, and ribociclib, primarily targeting the FOXM1 gene. Palbociclib, the first effective CDK4/6 inhibitor, benefits both post- and pre-menopausal women with HER2-negative and HR-positive BCa, with neutropenia being a common side effect. In certain combination therapies, pulmonary embolism, back pain, and diarrhoea were also observed (NCT02513394, NCT00141297, NCT01037790, NCT00721409, and NCT01942135) (119,120). In the AKT/PI3K/mTOR signalling pathway, AKT is a vital transducer affecting genes such as PI3K, FOXO1, PIP2, PDK1, TSC1/2, and mTOR. Activated AKT suppresses apoptotic pathways (Bcl-2-associated death promoter) while stimulating cell proliferation pathways. Both allosteric and ATP-competitive inhibitors have been designed, with ATP-competitive AKT inhibitors proving superior. MK-2206, an allosteric inhibitor, used in combination therapy with trastuzumab, anthracycline, and neoadjuvant chemotherapy, was particularly effective for HER2-positive BCa. Capivasertib and ipatasertib have demonstrated better efficacy than other ATP-competitive inhibitors (121). Advances in HER2-targeted malignancy treatments have led to increased survival rates for HER2-positive BCa patients (122). CAR T-cell immunotherapy plays a crucial role in addressing the clinical challenge of BCa metastasis. HER2-redirected chimeric T-cell receptor immunotherapy can trigger a remarkable immunological response in xenograft models (123). This third-generation CAR T-cell therapy, featuring the CD28 or 4-1BB co-stimulatory domain, enhances survival, proliferation, and cancer cell control by CAR T-cells (124). Approximately 20-30% of patients with HER2 amplification with adverse prognostic outcomes have been administered HER2/ERBB2 targeting the tyrosine kinase receptors that are responsible for activating the downstream signalling pathways such as P13K, MEK, PKC, and JAK/STAT once triggered, leading to tumour progression (125). The FDA-approved mAB trastuzumab targets HER2 receptors and has resulted in clinical improvements for BCa patients (126). The clinical trial [NCT02792114] identified MSLN as a prospective therapeutic target for MSLN-specific metastatic BCa. To optimize tumour specificity, the in vitro CAR T-cell therapy has been developed for targeting MUC1 and ERBB2 for BCa patients, resulting in T-cell survival within malignant tumour cells (127). Targeting the env gene of human endogenous retroviruses (HERV)-K with HERV-K-targeted CAR T-cell therapy has demonstrated anti-malignant effects, as the env protein is involved in tumour progression and is expressed in ~70% of BCa cases (128,129). Approximately 15-30% of BCa patients have HER1 gene amplification; primarily in cases of TNBC (130). TNBC is resistant to conventional (anti-HER2 and endocrine) treatments due to the absence of EGFR, oestrogen receptors (ERs), and progesterone receptors (PRs) (131). TNBC occurs in 45-70% of patients (132). Several target antigens for TNBC, such as chondroitin sulphate proteoglycan 4 (CSPG4), intracellular adhesion molecule-1 (ICAM-1), natural killer group 2 member D ligand (NKG2DL), AXL, tumour endothelial marker 8 (TEM8), integrin αVβ3, orphan receptor 1 (ROR1), c-MET, folate receptor α (FRα), EGFR, mesothelin, disialoganglioside (GD2), mucin 1 (MUC1), and trophoblast cell-surface antigen 2 (TROP2), have been identified (133) Atezolizumab, an anti-PD L1-based immunotherapy, in combination with the chemotherapeutic drug nab-paclitaxel, is used for TNBC treatment (134). Other promising target antigens are currently in the preclinical stage. Based on the results of nano-ultra performance liquid chromatography, five antigens have been identified, namely, IL-32, syntenin-1, ribophorin-2, proliferating cell nuclear antigen, and cofilin-1 (135). Targeting these tumour antigens may replace chemotherapy treatments and serve as a future approach for reprogramming CAR T-cells for TNBC treatment.

10. Limitations

The remarkable success of these engineered chimeric receptors in treating B-cell and haematological malignancies has made them a considerable and promising therapeutic option for B-cell tumours and haematological cancers. Despite being one of the most advanced therapies against malignancies, CAR T-cell therapy has several potential toxicities, including CRS, NT, on/off-target tumour detection, and induction of anaphylaxis (159,160). Additionally, there are certain challenges that arise during the treatment of solid tumours such as BCa and TNBC, including antigen escape (161) and an immunosuppressive tumour microenvironment (162).

CRS

CRS is an unfavourable inflammatory response that can occur during CAR T-cell therapy and mAB infusions. CRS is triggered by the activation of NK cells, B-lymphocytes, T-lymphocytes, phagocytic cells, APCs, and certain endothelial tissue matrix cells (163,164). CRS is witnessed following the infusion of mAbs, IL2, and certain bispecific CAR T-cell domains such as CD19-CD3 antibodies. The severity of CRS depends on the tumour burden in the patient. For instance, a case report by Teachey et al (165) noted that patients with relapsed/refractory B-ALL who received CD19-specific CAR T-cell immunotherapy experienced complications, including high levels of CRS (19-43%).

Corticosteroids play a significant role in reversing CRS symptoms without affecting the drug's anti-malignant effect. However, it is worth noting that prolonged systemic corticosteroid use for >14 days can have adverse effects on the drug's anti-carcinogenic effects. To address this concern, the FDA approved tocilizumab as a rapid reversal drug for CRS (166-169).

On/off-target carcinogen recognition

On/Off-target toxicity occurs when the intended target carcinogen is primarily present in cancerous cells but also binds to CAR T-cell target antigens in non-malignant tissues. This toxicity has been observed in gastrointestinal and haematologic organ systems (170). The first instance of on/off-target toxicity was observed in renal cell carcinoma patients who were treated with chimeric antigen-recognising carbonic anhydrase IX (CAIX) (171).

A study conducted by Morgan et al (172) observed toxicity in colorectal cancer patients who received third-generation CAR T-cell therapy targeting CRBB2/HER2. To mitigate the extent of long-term toxicities such as those mentioned above, suicidal genes can be introduced into the vector (172,173).

Patients receiving CAR T-cell therapy for CD19-specific neoplasms may experience focal neurological symptoms, including aphasia, seizures, allodynia, and apraxia (174). Importantly, the severity of neurological sequelae can be partially influenced by the cytokine levels of the patient. For example, 78% of B-cell NHL patients who received axicabtagene ciloleucel experienced NT, and 87% of B-ALL patients treated with brexucabtagene autoleucel suffered from neurologic toxicities. Studies have shown no clear correlation between the proportion of modified and naturally occurring T-cells and the presence of EEG abnormalities. It remains unclear whether NT is specific to CD19-specific malignancies or can occur with other antigens (175).

Anaphylaxis

Anaphylaxis occurs when the body's natural defence system overreacts and triggers an excessive inflammatory response. The primary reason for anaphylaxis in CAR T-cell therapy is the use of chimeric T-lymphocytic receptors derived from murine mAbs (175,176). Mesothelin, a tumour-associated antigen, is often overexpressed in malignancies such as malignant pleural mesothelioma (MPM), pancreatic cancer, and ovarian cancer. Preclinical models showed that multiple infusions of anti-mesothelin and anti-CD19 RNA CAR T-cells had anti-tumour effects. Based on this, human clinical trials were conducted (NCT01355965) involving meso-RNA-CAR T therapy. However, multiple meso-mRNA CAR T-cell infusions in a limited time frame resulted in a patient experiencing an anaphylactic shock. To mitigate this toxicity, T-cell infusion was terminated (177-179). The transfer of genetically engineered T-cells requires careful monitoring, prompt recognition, and immediate management of these side effects to reduce any potential negative outcomes.

Toxicities in BCa and TNBC

One major limitation when targeting BCa antigens is the proper identification of the target antigen due to its low expression levels in vital organs, which could lead to off-target toxic effects (114). Another toxic outcome when targeting these receptors on proliferating cells in breast tissues is intratumor heterogeneity, which causes resistance of tumour antigens to single target engineered receptors, a phenomenon known as antigen escape. In antigen escape, engineered CAR T-cells lose their efficacy against carcinogens. To counteract this toxicity, several preclinical experiments have combined dual antigens to target solid tumours, which eventually improves treatment efficacy. For example, several tandem chimeric receptors, including HER2 and MUC1 in BCa, have shown enhanced anti-carcinogenic effects in preclinical models. Another significant challenge of CAR T-cell therapy in solid tumours, particularly in BCa, is associated with an immunosuppressive TME. The TME is comprised of multiple immunosuppressive elements, including carcinogenic cells, regulatory T-lymphocytes (Treg), myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts, and tumour-associated macrophages (TAMs). Additionally, various cytokines, chemokines, and extracellular matrix components are integral parts of the TME that help in regulating progression, angiogenesis, and metastasis by providing necessary growth regulators, chemokines, interleukins, transforming growth factor-β (TGF-β), indoleamine 2,3-dioxygenase (IDO), and vascular endothelial growth factor. PD-1 and CTLA-4 are other immunosuppressive checkpoint blockers that affect chimeric-engineered T-receptors, hindering their anti-carcinogenic reactions against solid tumours such as TNBC (180-183). A strategy to combat the immunosuppressive TME involves engineering armoured CARs that release pro-inflammatory cytokines to favourably reshape anti-carcinogenic responses. Interleukins such as IL-12 and IL-18 are released to enhance anti-carcinogenic reactions by IFNγ and Treg inhibition that triggers M1 macrophages (184,185).

11. Conclusions and future perspectives

A significant barrier leading to on/off-target tumour toxicity in solid tumours associated with TAAs is the challenge of specifically targeting tumour cells. New CAR designs are being developed with improved tumour selectivity and reduced off-target effects. This includes the use of synthetic receptors such as synNotch receptors to enhance the specificity of CAR T-cells. Another hurdle is TME, in which solid tumours release chemotactic cytokines such as CXCL1, CXCL12, and CXCL5, which suppress T-cell activation (186,187). To overcome these challenges, additional proteins such as armoured CAR T-cells are incorporated into engineered receptors to withstand immunosuppressive responses primarily found in TME to improve the eradication of tumours. The incorporation of 'suicide genes' into CARs also provides an opportunity to mitigate toxicity by deactivating the CAR T-cells (188,189). TNBCs, which have historically been challenging to treat and often rely on chemotherapy with low survival rates, are now the focus of several combination therapies in preliminary and interventional trials. Examples include CDK7 with EGFR CAR therapy (190) and anti-PD-L1 with PARP inhibitory therapy (190). Researchers are continually exploring various methods to overcome these obstacles, such as integrating CRISPR/Cas9 systems into CAR immunotherapy for genome editing and the development of universal CAR T-cells (190,191). Advances in multi-omics have improved the ability to identify unique neoantigens resulting from tumour-specific polymorphisms, potentially leading to more targeted therapies with fewer adverse effects (192).

The potential developments in CAR T-cell therapy are promising and marked by significant advancements. As technology progresses, the field may witness increased safety measures, innovative target identification, combination therapies, an increased range of tools, and breakthroughs in manufacturing and delivery. These developments are likely to shape the landscape of precision immunotherapy, highlighting novel avenues for more effective and personalised cancer treatments. The unwavering dedication of researchers, healthcare professionals, and industry stakeholders will pave the way for a future where CAR T-cell immunotherapy proves highly effective in treating sarcomas, ultimately improving patient outcomes (193).

Overall, the potential of CAR T-cells in treating solid tumours, including BCa and TNBC, has yielded promising results in clinical trials. The label of being 'difficult to treat' for TNBCs may soon be erased through the effective outcomes achievable with these engineered receptors.

Availability of data and materials

Not applicable.

Authors' contributions

MZN, S, wrote the major parts of the manuscript and prepared the figures and tables. CD and SG revised the manuscript. HEME, FHK, AAE and NT performed the bibliographic research and prepared the table and figures. MAK conceptualized the study and oversaw the process. All authors helped to write the manuscript. All authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

Not applicable.

Funding

This research has been funded by Scientific Research Deanship at University of Ha'il-Saudi Arabia through project number MDR-22 038.

References

1	National Cancer Institute: What is cancer? 2021, https://www.cancer.gov/about-cancer/understanding/what-is-cancer.
2	Blackadar CB: Historical review of the causes of cancer. World J Clin Oncol. 7:54–86. 2016. View Article : Google Scholar : PubMed/NCBI
3	Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK and Manyazewal T: New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 9:205031212110343662021. View Article : Google Scholar : PubMed/NCBI
4	Decker WK and Safdar A: Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev. 20:271–281. 2009. View Article : Google Scholar : PubMed/NCBI
5	Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger JM, Kerjaschki D, Stingl G, et al: Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine. J Innate Immun. 8:111–120. 2016. View Article : Google Scholar : PubMed/NCBI
6	Rosenberg SA: IL-2: The first effective immunotherapy for human cancer. J Immunol. 192:5451–5458. 2014. View Article : Google Scholar : PubMed/NCBI
7	Pierpont TM, Limper CB and Richards KL: Past, present, and future of rituximab-the world's first oncology monoclonal antibody therapy. Front Oncol. 8:163. 2018. View Article : Google Scholar : PubMed/NCBI
8	June CH, O'Connor RS, Kawalekar OU, Ghassemi S and Milone MC: CAR T cell immunotherapy for human cancer. Science. 359:1361–1365. 2018. View Article : Google Scholar : PubMed/NCBI
9	Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME: Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
10	Gross G, Waks T and Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 86:10024–10028. 1989. View Article : Google Scholar : PubMed/NCBI
11	Graham C, Hewitson R, Pagliuca A and Benjamin R: Cancer immunotherapy with CAR-T cells-behold the future. Clin Med (Lond). 18:324–328. 2018. View Article : Google Scholar : PubMed/NCBI
12	Maus MV: A decade of CAR T cell evolution. Nat Cancer. 3:270–271. 2022. View Article : Google Scholar : PubMed/NCBI
13	Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, et al: Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 5:197ra1032013. View Article : Google Scholar : PubMed/NCBI
14	June CH, Riddell SR and Schumacher TN: Adoptive cellular therapy: A race to the finish line. Sci Transl Med. 7:280ps72015. View Article : Google Scholar : PubMed/NCBI
15	Lee YH and Kim CH: Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Arch Pharm Res. 42:607–616. 2019. View Article : Google Scholar : PubMed/NCBI
16	Titov A, Valiullina A, Zmievskaya E, Zaikova E, Petukhov A, Miftakhova R, Bulatov E and Rizvanov A: Advancing CAR T-cell therapy for solid tumors: Lessons learned from lymphoma treatment. Cancers (Basel). 12:1252020. View Article : Google Scholar : PubMed/NCBI
17	Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY and Zhao W: CAR-T design: Elements and their synergistic function. EBioMedicine. 58:1029312020. View Article : Google Scholar : PubMed/NCBI
18	Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, Momin N, Pishesha N, Rickelt S, Hynes RO and Ploegh H: Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci USA. 116:7624–7631. 2019. View Article : Google Scholar : PubMed/NCBI
19	Barber A, Rynda A and Sentman CL: Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 183:6939–6947. 2009. View Article : Google Scholar : PubMed/NCBI
20	Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS and Powell DJ Jr: High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 30:1355–1364. 2016. View Article : Google Scholar : PubMed/NCBI
21	Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, et al: The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens. J Immunother. 28:203–211. 2005. View Article : Google Scholar : PubMed/NCBI
22	Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC and Riddell SR: The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 3:125–135. 2015. View Article : Google Scholar
23	Zhang C, Liu J, Zhong JF and Zhang X: Engineering CAR-T cells. Biomark Res. 5:222017. View Article : Google Scholar : PubMed/NCBI
24	Sterner RC and Sterner RM: CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 11:692021. View Article : Google Scholar : PubMed/NCBI
25	Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P and Ganguly N: CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep. 42:2183–2195. 2019.PubMed/NCBI
26	Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, Liu S and Ma J: CAR-T cell therapy in cancer: Tribulations and road ahead. J Immunol Res. 2020:19243792020. View Article : Google Scholar : PubMed/NCBI
27	Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 118:6050–6056. 2011. View Article : Google Scholar : PubMed/NCBI
28	Duong CP, Yong CS, Kershaw MH, Slaney CY and Darcy PK: Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Mol Immunol. 67:46–57. 2015. View Article : Google Scholar : PubMed/NCBI
29	Qian L, Li D, Ma L, He T, Qi F, Shen J and Lu XA: The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Cell Immunol. 304:49–54. 2016. View Article : Google Scholar : PubMed/NCBI
30	Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, Kolbe C, Al Rawashdeh W, Brauner J, Hardt O, et al: Automated manufacturing of potent CD20-directed chimeric antigen receptor t cells for clinical use. Hum Gene Ther. 28:914–925. 2017. View Article : Google Scholar : PubMed/NCBI
31	Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J and Sadelain M: Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 28:415–428. 2015. View Article : Google Scholar : PubMed/NCBI
32	Hombach A, Hombach AA and Abken H: Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target'activation and unintended initiation of an innate immune response. Gene Ther. 17:1206–1213. 2010. View Article : Google Scholar : PubMed/NCBI
33	Zhong XS, Matsushita M, Plotkin J, Riviere I and Sadelain M: Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 18:413–420. 2010. View Article : Google Scholar
34	Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, et al: Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 7:e14335182018. View Article : Google Scholar : PubMed/NCBI
35	Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, et al: A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 25:1003–1012. 2014. View Article : Google Scholar : PubMed/NCBI
36	Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM and Brenner MK: A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 12:933–941. 2005. View Article : Google Scholar : PubMed/NCBI
37	Beatty GL and Moon EK: Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology. 3:e9700272014. View Article : Google Scholar
38	Chmielewski M and Abken H: TRUCKs: The fourth generation of CARs. Expert Opin Biol Ther. 15:1145–1154. 2015. View Article : Google Scholar : PubMed/NCBI
39	Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE and Gilham DE: CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol Ther Oncolytics. 8:41–51. 2017. View Article : Google Scholar
40	John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH and Darcy PK: Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 19:5636–5646. 2013. View Article : Google Scholar : PubMed/NCBI
41	Kim DW and Cho JY: Recent advances in allogeneic CAR-T cells. Biomolecules. 10:2632020. View Article : Google Scholar : PubMed/NCBI
42	Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD and Hirano N: A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 24:352–359. 2018. View Article : Google Scholar : PubMed/NCBI
43	Dai H, Wang Y, Lu X and Han W: Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 108:djv4392016. View Article : Google Scholar : PubMed/NCBI
44	Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, Yang X, Sun J, Li Z, Han WD and Wang W: Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther. 4:352019. View Article : Google Scholar : PubMed/NCBI
45	Levine BL, Miskin J, Wonnacott K and Keir C: Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 4:92–101. 2016. View Article : Google Scholar
46	Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S and Kobold S: Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 20:12832019. View Article : Google Scholar : PubMed/NCBI
47	Guo S and Deng CX: Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 14:2083–2093. 2018. View Article : Google Scholar : PubMed/NCBI
48	Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, et al: XactMice: Humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene. 35:290–300. 2016. View Article : Google Scholar
49	Najima Y, Tomizawa-Murasawa M, Saito Y, Watanabe T, Ono R, Ochi T, Suzuki N, Fujiwara H, Ohara O, Shultz LD, et al: Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood. 127:722–734. 2016. View Article : Google Scholar :
50	Yin L and Wang XJ, Chen DX, Liu XN and Wang XJ: Humanized mouse model: A review on preclinical applications for cancer immunotherapy. Am J Cancer Res. 10:4568–4584. 2020.
51	Zitvogel L, Pitt JM, Daillère R, Smyth MJ and Kroemer G: Mouse models in on immunology. Nat Rev Cancer. 16:759–773. 2016. View Article : Google Scholar : PubMed/NCBI
52	Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, Krönke N, Feuerhake F, Ferreira de Figueiredo C, Blasczyk R, et al: CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther Oncolytics. 18:504–524. 2020. View Article : Google Scholar : PubMed/NCBI
53	Jin CH, Xia J, Rafiq S, Huang X, Hu Z, Zhou X, Brentjens RJ and Yang YG: Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine. 39:173–181. 2019. View Article : Google Scholar :
54	Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, et al: Aberrant Lck signal via CD28 costimulation augments antigen-specific functionality and tumor control by redirected T cells with PD-1 blockade in humanized mice. Clin Cancer Res. 24:3981–3993. 2018. View Article : Google Scholar : PubMed/NCBI
55	Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014. View Article : Google Scholar
56	Szöőr Á, Tóth G, Zsebik B, Szabó V, Eshhar Z, Abken H and Vereb G: Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 484:1–8. 2020. View Article : Google Scholar
57	Liu Y, Zhou Y, Huang KH, Li Y, Fang X, An L, Wang F, Chen Q, Zhang Y, Shi A, et al: EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging (Albany NY). 11:11054–11072. 2019. View Article : Google Scholar : PubMed/NCBI
58	Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G and Fusco N: CAR-T cell therapy for triple-negative breast cancer and other solid tumors: Preclinical and clinical progress. Expert Opin Investig Drugs. 31:593–605. 2022. View Article : Google Scholar : PubMed/NCBI
59	Wei J, Sun H, Zhang A, Wu X, Li Y, Liu J, Duan Y, Xiao F, Wang H, Lv M, et al: A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers. Cell Immunol. 331:49–58. 2018. View Article : Google Scholar : PubMed/NCBI
60	Wallstabe L, Mades A, Frenz S, Einsele H, Rader C and Hudecek M: CAR T cells targeting α_vβ₃ integrin are effective against advanced cancer in preclinical models. Adv Cell Gene Ther. 1:e112018. View Article : Google Scholar
61	Zhao X, Qu J, Hui Y, Zhang H, Sun Y, Liu X, Zhao X, Zhao Z, Yang Q, Wang F and Zhang S: Clinicopathological and prognostic significance of c-Met overexpression in breast cancer. Oncotarget. 8:56758–56767. 2017. View Article : Google Scholar : PubMed/NCBI
62	Han Y, Xie W, Song DG and Powell DJ Jr: Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 11:922018. View Article : Google Scholar : PubMed/NCBI
63	Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J and Mukherjee P: CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 10:11492019. View Article : Google Scholar : PubMed/NCBI
64	Wallstabe L, Göttlich C, Nelke LC, Kühnemundt J, Schwarz T, Nerreter T, Einsele H, Walles H, Dandekar G, Nietzer SL and Hudecek M: ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 4:e1263452019. View Article : Google Scholar : PubMed/NCBI
65	Zhao Z, Li Y, Liu W and Li X: Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer. Biomed Res Int. 2020:47951712020.PubMed/NCBI
66	Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, et al: In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. Int J Cancer. 146:236–247. 2020. View Article : Google Scholar
67	Song DG, Ye Q, Poussin M, Chacon JA, Figini M and Powell DJ Jr: Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 9:562016. View Article : Google Scholar : PubMed/NCBI
68	Seitz CM, Schroeder S, Knopf P, Krahl AC, Hau J, Schleicher S, Martella M, Quintanilla-Martinez L, Kneilling M, Pichler B, et al: GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 9:16833452019. View Article : Google Scholar
69	Yang Y, Vedvyas Y, McCloskey JE, Min IM and Jin MM: ICAM-1 targeting CAR T cell therapy for triple negative breast cancer. Cancer Res. 79(13 Suppl): S23222019. View Article : Google Scholar
70	Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X and Wei F: CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother. 68:365–377. 2019. View Article : Google Scholar
71	Petrovic K, Robinson J, Whitworth K, Jinks E, Shaaban A and Lee SP: TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo. PLoS One. 14:e02240152019. View Article : Google Scholar : PubMed/NCBI
72	Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, et al: TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res. 78:489–500. 2018. View Article : Google Scholar :
73	Bedoya DM, King T and Posey AD: Generation of CART cells targeting oncogenic TROP2 for the elimination of epithelial malignancies. Cytotherapy. 21(Suppl): S11–S12. 2019. View Article : Google Scholar
74	National Library of Medicine (NLM): Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma. ClinicalTrials.gov ID, NCT02208362. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/study/NCT02208362.
75	National Library of Medicine (NLM): CART-EGFRvIII + Pembrolizumab in GBM. ClinicalTrials.gov ID, NCT03726515. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03726515.
76	National Library of Medicine (NLM): GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression. ClinicalTrials.gov ID, NCT03198546. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03198546.
77	National Library of Medicine (NLM): Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma. ClinicalTrials.gov ID, NCT00902044. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT00902044.
78	National Library of Medicine (NLM): CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells (HITM). ClinicalTrials.gov ID, NCT01373047. NLM; Bethesda, MD: 2011, https://clinicaltrials.gov/ct2/show/NCT01373047.
79	National Library of Medicine (NLM): Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer. ClinicalTrials.gov ID, NCT01897415. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01897415.
80	National Library of Medicine (NLM): CAR T Cell Immunotherapy for Pancreatic Cancer. ClinicalTrials.gov ID, NCT03323944. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03323944.
81	National Library of Medicine (NLM): Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma. ClinicalTrials.gov ID, NCT03159819. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03159819.
82	National Library of Medicine (NLM): Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma. ClinicalTrials.gov ID, NCT03393936. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03393936.
83	National Library of Medicine (NLM): PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer. ClinicalTrials.gov ID, NCT03873805. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03873805.
84	National Library of Medicine (NLM): CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer. ClinicalTrials.gov ID, NCT03089203. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03089203.
85	National Library of Medicine (NLM): Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*). ClinicalTrials.gov ID, NCT04020575. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04020575.
86	National Library of Medicine (NLM): MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. ClinicalTrials.gov ID, NCT03585764. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03585764.
87	National Library of Medicine (NLM): Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors. ClinicalTrials.gov ID, NCT02498912. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02498912.
88	National Library of Medicine (NLM): T-Cell Therapy for Advanced Breast Cancer. ClinicalTrials.gov ID, NCT02792114. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02792114.
89	National Library of Medicine (NLM): T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR). ClinicalTrials.gov ID, NCT02442297. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02442297.
90	National Library of Medicine (NLM): HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases. ClinicalTrials.gov ID, NCT03696030. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03696030.
91	National Library of Medicine (NLM): Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin. ClinicalTrials.gov ID, NCT02414269. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02414269.
92	National Library of Medicine (NLM): Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19. ClinicalTrials.gov ID, NCT01044069. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT01044069.
93	National Library of Medicine (NLM): Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19. ClinicalTrials.gov ID, NCT00466531. NLM; Bethesda, MD: 2007, https://clinicaltrials.gov/ct2/show/NCT00466531.
94	National Library of Medicine (NLM): CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH). ClinicalTrials.gov ID, NCT00586391. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00586391.
95	National Library of Medicine (NLM): CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH). ClinicalTrials.gov ID, NCT00608270. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00608270.
96	National Library of Medicine (NLM): Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies. ClinicalTrials.gov ID, NCT02315612. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT02315612.
97	National Library of Medicine (NLM): Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma. ClinicalTrials.gov ID, NCT01722149. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT01722149.
98	National Library of Medicine (NLM): Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01. ClinicalTrials.gov ID, NCT02311621. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT02311621.
99	National Library of Medicine (NLM): Study of bb21217 in Multiple Myeloma. ClinicalTrials.gov ID, NCT03274219. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03274219.
100	National Library of Medicine (NLM): Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL). ClinicalTrials.gov ID, NCT00881920. NLM; Bethesda, MD: 2009, https://clinicaltrials.gov/ct2/show/NCT00881920.
101	National Library of Medicine (NLM): KSafety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA). ClinicalTrials.gov ID, NCT03939026. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03939026.
102	National Library of Medicine (NLM): Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL. ClinicalTrials.gov ID, NCT03666000. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT03666000.
103	National Library of Medicine (NLM): A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON). ClinicalTrials.gov ID, NCT04035434. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04035434.
104	National Library of Medicine (NLM): Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMELI-01). ClinicalTrials.gov ID, NCT03190278. NLM; Bethesda, MD: 2017, https://clinicaltrials.gov/ct2/show/NCT03190278.
105	National Library of Medicine (NLM): Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL). ClinicalTrials.gov ID, NCT04093596. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04093596.
106	National Library of Medicine (NLM): SaalloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK). ClinicalTrials.gov ID, NCT03692429. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03692429.
107	National Library of Medicine (NLM): Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC). ClinicalTrials.gov ID, NCT01140373. NLM; Bethesda, MD: 2010, https://clinicaltrials.gov/ct2/show/NCT01140373.
108	National Library of Medicine (NLM): 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN). ClinicalTrials.gov ID, NCT01822652. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01822652.
109	National Library of Medicine (NLM): iC9-GD2-CARVZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (VEGAS). ClinicalTrials.gov ID, NCT01953900. NLM; Bethesda, MD: 2014, https://clinicaltrials.gov/ct2/show/NCT01953900.
110	Almond LM, Charalampakis M, Ford SJ, Gourevitch D and Desai A: Myeloid sarcoma: Presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 17:263–267. 2017. View Article : Google Scholar : PubMed/NCBI
111	Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, et al: Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 25:285–295. 2017. View Article : Google Scholar : PubMed/NCBI
112	Jain MD, Bachmeier CA, Phuoc VH and Chavez JC: Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. Ther Clin Risk Manag. 14:1007–1017. 2018. View Article : Google Scholar : PubMed/NCBI
113	Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, et al: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet. 396:839–852. 2020. View Article : Google Scholar : PubMed/NCBI
114	Abbott RC, Cross RS and Jenkins MR: Finding the keys to the CAR: Identifying novel target antigens for T cell redirection immunotherapies. Int J Mol Sci. 21:5152020. View Article : Google Scholar : PubMed/NCBI
115	Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al: Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 44:1444–1454. 2016. View Article : Google Scholar : PubMed/NCBI
116	Li X, Ding Y, Zi M, Sun L, Zhang W, Chen S and Xu Y: CD19, from bench to bedside. Immunol Lett. 183:86–95. 2017. View Article : Google Scholar : PubMed/NCBI
117	Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al: Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 33:16882015. View Article : Google Scholar : PubMed/NCBI
118	Cortesi L, Rugo HS and Jackisch C: An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 16:255–282. 2021. View Article : Google Scholar : PubMed/NCBI
119	Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK and Tang H: Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 22:1052023. View Article : Google Scholar : PubMed/NCBI
120	Schoninger SF and Blain SW: The ongoing search for biomarkers of CDK4/6 inhibitor responsiveness in breast cancer. Mol Cancer Ther. 19:3–12. 2020. View Article : Google Scholar : PubMed/NCBI
121	Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR, Manzella L and Vigneri P: AKT inhibitors: New weapons in the fight against breast cancer? Front Pharmacol. 12:6622322021. View Article : Google Scholar : PubMed/NCBI
122	Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF and Schiff R: Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 17:233–250. 2020. View Article : Google Scholar
123	Tóth G, Szöllősi J, Abken H, Vereb G and Szöőr Á: A small number of HER2 redirected CAR T cells significantly improves immune response of adoptively transferred mouse lymphocytes against human breast cancer xenografts. Int J Mol Sci. 21:10392020. View Article : Google Scholar : PubMed/NCBI
124	Toulouie S, Johanning G and Shi Y: Chimeric antigen receptor T-cell immunotherapy in breast cancer: Development and challenges. J Cancer. 12:1212–1219. 2021. View Article : Google Scholar : PubMed/NCBI
125	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
126	Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:4285–4289. 1992. View Article : Google Scholar : PubMed/NCBI
127	Bou-Dargham MJ, Draughon S, Cantrell V, Khamis ZI and Sang QA: Advancements in human breast cancer targeted therapy and immunotherapy. J Cancer. 12:6949–6963. 2021. View Article : Google Scholar : PubMed/NCBI
128	Rivas SR, Valdez MJM, Govindarajan V, Seetharam D, Doucet-O'Hare TT, Heiss JD and Shah AH: The role of HERV-K in cancer stemness. Viruses. 14:20192022. View Article : Google Scholar : PubMed/NCBI
129	Zhao J, Rycaj K, Geng S, Li M, Plummer JB, Yin B, Liu H, Xu X, Zhang Y, Yan Y, et al: Expression of human endogenous retrovirus type K envelope protein is a novel candidate prognostic marker for human breast cancer. Genes Cancer. 2:914–922. 2011. View Article : Google Scholar
130	Pegram M and Slamon D: Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 27(Suppl 9): S13–S19. 2000.
131	Walsh EM, Keane MM, Wink DA, Callagy G and Glynn SA: Review of triple negative breast cancer and the impact of inducible nitric oxide synthase on tumor biology and patient outcomes. Crit Rev Oncog. 21:333–351. 2016. View Article : Google Scholar : PubMed/NCBI
132	Tsutsui S, Ohno S, Murakami S, Hachitanda Y and Oda S: Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 71:67–75. 2002. View Article : Google Scholar : PubMed/NCBI
133	Nasiri F, Kazemi M, Mirarefin SMJ, Mahboubi Kancha M, Ahmadi Najafabadi M, Salem F, Dashti Shokoohi S, Evazi Bakhshi S and Safarzadeh Kozani P and Safarzadeh Kozani P: CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Front Immunol. 13:10187862022. View Article : Google Scholar : PubMed/NCBI
134	Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, et al: PARP inhibitor efficacy depends on CD8⁺ T-cell recruitment via intratumoral sting pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9:722–737. 2019. View Article : Google Scholar : PubMed/NCBI
135	Ternette N, Olde Nordkamp MJM, Müller J, Anderson AP, Nicastri A, Hill AVS, Kessler BM and Li D: Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens. Proteomics. 18:17004652018. View Article : Google Scholar : PubMed/NCBI
136	National Library of Medicine (NLM): Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection. ClinicalTrials.gov ID, NCT04164615. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04164615.
137	National Library of Medicine (NLM): Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer. ClinicalTrials.gov ID, NCT04329065. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04329065.
138	National Library of Medicine (NLM): Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab. ClinicalTrials.gov ID, NCT04276493. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04276493.
139	National Library of Medicine (NLM): Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection. ClinicalTrials.gov ID, NCT04170595. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04170595.
140	National Library of Medicine (NLM): A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases. ClinicalTrials.gov ID, NCT03500380. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03500380.
141	National Library of Medicine (NLM): Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2. ClinicalTrials.gov ID, NCT00019812. NLM; Bethesda, MD: 2003, https://clinicaltrials.gov/ct2/show/NCT00019812.
142	National Library of Medicine (NLM): Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT00003539. NLM; Bethesda, MD: 2004, https://clinicaltrials.gov/ct2/show/NCT00003539.
143	National Library of Medicine (NLM): Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT00006228. NLM; Bethesda, MD: 2003, https://clinicaltrials.gov/ct2/show/NCT00006228.
144	National Library of Medicine (NLM): Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2. ClinicalTrials.gov ID, NCT00003992. NLM; Bethesda, MD: 2004, https://clinicaltrials.gov/ct2/show/NCT00003992.
145	National Library of Medicine (NLM): Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02). ClinicalTrials.gov ID, NCT03571633. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03571633.
146	National Library of Medicine (NLM): A Study of Pertuzumab in Participants With Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT02491892. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02491892.
147	National Library of Medicine (NLM): Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab. ClinicalTrials.gov ID, NCT00301899. NLM; Bethesda, MD: 2006, https://clinicaltrials.gov/ct2/show/NCT00301899.
148	National Library of Medicine (NLM): A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer. ClinicalTrials.gov ID, NCT04924699. NLM; Bethesda, MD: 2021, https://clinicaltrials.gov/ct2/show/NCT04924699.
149	National Library of Medicine (NLM): ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03). ClinicalTrials.gov ID, NCT04829604. NLM; Bethesda, MD: 2021, https://clinicaltrials.gov/ct2/show/NCT04829604.
150	National Library of Medicine (NLM): Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour. ClinicalTrials.gov ID, NCT04107142. NLM; Bethesda, MD: 2019, https://clinicaltrials.gov/ct2/show/NCT04107142.
151	National Library of Medicine (NLM): A Study to Investigate LYL797 in Adults With Solid Tumors. ClinicalTrials.gov ID, NCT05274451. NLM; Bethesda, MD: 2022, https://clinicaltrials.gov/ct2/show/NCT05274451.
152	National Library of Medicine (NLM): A Biomarker Screening Protocol for Participants With Solid Tumors (START). ClinicalTrials.gov ID, NCT05891197. NLM; Bethesda, MD: 2023, https://clinicaltrials.gov/ct2/show/NCT05891197.
153	National Library of Medicine (NLM): cMet CAR RNA T Cells Targeting Breast Cancer. ClinicalTrials.gov ID, NCT01837602. NLM; Bethesda, MD: 2013, https://clinicaltrials.gov/ct2/show/NCT01837602.
154	National Library of Medicine (NLM): Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso. ClinicalTrials.gov ID, NCT02580747. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02580747.
155	National Library of Medicine (NLM): Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor. ClinicalTrials.gov ID, NCT02587689. NLM; Bethesda, MD: 2015, https://clinicaltrials.gov/ct2/show/NCT02587689.
156	National Library of Medicine (NLM): Multi-4SCAR-T Therapy Targeting Breast Cancer. ClinicalTrials.gov ID, NCT04430595. NLM; Bethesda, MD: 2020, https://clinicaltrials.gov/ct2/show/NCT04430595.
157	National Library of Medicine (NLM): EpCAM CAR-T for Treatment of Advanced Solid Tumors. ClinicalTrials.gov ID, NCT02915445. NLM; Bethesda, MD: 2016, https://clinicaltrials.gov/ct2/show/NCT02915445.
158	National Library of Medicine (NLM): C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N). ClinicalTrials.gov ID, NCT03635632. NLM; Bethesda, MD: 2018, https://clinicaltrials.gov/ct2/show/NCT03635632.
159	Bonifant CL, Jackson HJ, Brentjens RJ and Curran KJ: Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 3:160112016. View Article : Google Scholar : PubMed/NCBI
160	Almåsbak H, Aarvak T and Vemuri MC: CAR T cell therapy: A game changer in cancer treatment. J Immunol Res. 2016:54746022016. View Article : Google Scholar : PubMed/NCBI
161	Abreu TR, Fonseca NA, Gonçalves N and Moreira JN: Current challenges and emerging opportunities of CAR-T cell therapies. J Control Release. 319:246–261. 2020. View Article : Google Scholar : PubMed/NCBI
162	Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH and Sherwin SA: Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 5:222017. View Article : Google Scholar : PubMed/NCBI
163	Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, et al: Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. 13:610–617. 2019. View Article : Google Scholar : PubMed/NCBI
164	Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI
165	Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, et al: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 121:5154–5157. 2013. View Article : Google Scholar : PubMed/NCBI
166	Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 385:517–528. 2015. View Article : Google Scholar
167	Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119:2709–2720. 2012. View Article : Google Scholar :
168	Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 5:177ra382013. View Article : Google Scholar : PubMed/NCBI
169	Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368:1509–1518. 2013. View Article : Google Scholar : PubMed/NCBI
170	Curran KJ, Pegram HJ and Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med. 14:405–415. 2012. View Article : Google Scholar : PubMed/NCBI
171	Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G and Oosterwijk E: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol. 24:e20–e22. 2006. View Article : Google Scholar : PubMed/NCBI
172	Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010. View Article : Google Scholar : PubMed/NCBI
173	Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A, Biagi E and Pule M: Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods. 23:376–386. 2012. View Article : Google Scholar : PubMed/NCBI
174	Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, Cote DJ, Spendley L, Kim AH, Robertson MS, et al: Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 142:1334–1348. 2019. View Article : Google Scholar : PubMed/NCBI
175	Miao L, Zhang Z, Ren Z and Li Y: Reactions related to CAR-T cell therapy. Front Immunol. 12:6632012021. View Article : Google Scholar : PubMed/NCBI
176	Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M and June CH: T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 1:26–31. 2013. View Article : Google Scholar
177	Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al: Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70:9053–9061. 2010. View Article : Google Scholar : PubMed/NCBI
178	Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH and Grupp SA: Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 22:1575–1586. 2011. View Article : Google Scholar : PubMed/NCBI
179	Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
180	Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ: The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138:105–115. 2013. View Article : Google Scholar :
181	Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA and Kang CY: Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: An alternative cell-based antitumor vaccine. J Immunol. 182:1818–1828. 2009. View Article : Google Scholar : PubMed/NCBI
182	Davis RJ, Van Waes C and Allen CT: Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 58:59–70. 2016. View Article : Google Scholar : PubMed/NCBI
183	Fedorov VD, Themeli M and Sadelain M: PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 5:215ra1722013. View Article : Google Scholar : PubMed/NCBI
184	Chmielewski M, Kopecky C, Hombach AA and Abken H: IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71:5697–5706. 2011. View Article : Google Scholar : PubMed/NCBI
185	Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M and Brentjens RJ: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 119:4133–4141. 2012. View Article : Google Scholar : PubMed/NCBI
186	Patel U, Abernathy J, Savani BN, Oluwole O, Sengsayadeth S and Dholaria B: CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 3(Suppl 1): S24–S31. 2022. View Article : Google Scholar
187	Włodarczyk M and Pyrzynska B: CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer. Cancers (Basel). 15:1172022. View Article : Google Scholar
188	Hawkins ER, D'Souza RR and Klampatsa A: Armored CAR T-cells: The next chapter in T-cell cancer immunotherapy. Biologics. 15:95–105. 2021.PubMed/NCBI
189	Rafiq S, Hackett CS and Brentjens RJ: Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 17:147–167. 2020. View Article : Google Scholar :
190	Xia L, Zheng Z, Liu JY, Chen YJ, Ding J, Hu GS, Hu YH, Liu S, Luo WX, Xia NS and Liu W: Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition. Cancer Immunol Res. 9:707–722. 2021. View Article : Google Scholar : PubMed/NCBI
191	Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, Liu X, Lv Z, Yang P, Xu W, et al: Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 20:1262021. View Article : Google Scholar : PubMed/NCBI
192	Yan T, Zhu L and Chen J: Current advances and challenges in CAR T-Cell therapy for solid tumors: Tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 12:142023. View Article : Google Scholar : PubMed/NCBI
193	Collins DC, Sundar R, Lim JSJ and Yap TA: Towards precision medicine in the clinic: From biomarker discovery to novel therapeutics. Trends Pharmacol Sci. 38:25–40. 2017. View Article : Google Scholar

December-2023
Volume 63 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Recommend to Library

Journal Metrics
Impact Factor: 5.2
Ranked Oncology
(total number of cites)
CiteScore: 11.4
CiteScore Rank: Q1: #40/366 Oncology
Source Normalized Impact per Paper (SNIP): 1.125
SCImago Journal Rank (SJR): 1.105

NCT number	Phase	Target antigen	(Refs.)
NCT04329065	Phase 2	HER2	(136)
NCT00095706	Phase 1/2-completed	HER2 +ve	(137)
NCT04276493	Phase 1/2	HER2 +ve	(138)
NCT04170595	Phase 1/2	HER2 +ve	(139)
NCT03500380	Phase 2/3	HER2 +ve	(140)
NCT00019812	Phase 2-completed	HER2	(141)
NCT00003539	Phase 2-completed	HER2	(142)
NCT00006228	Phase 2-completed	HER2 +ve	(143)
NCT00003992	Phase 2-completed	HER2	(144)
NCT03571633	Phase 2	HER2 +ve	(145)
NCT02491892	Phase 2-completed	HER2	(146)
NCT00301899	Phase 2-completed	HER2/neu	(147)
NCT04924699	Phase 2/3	HER2 +ve	(148)
NCT04829604	Phase 2	HER2 +ve	(149)
NCT04107142	Phase 1	NKG2DL	(150)
NCT05274451	Phase 1	ROR1+	(151)
NCT05891197	Early phase 1 (ongoing)	ROR1	(152)
NCT01837602	Phase 1-completed	c-MET	(153)
NCT02580747	Phase 1	Mesothelin	(154)
NCT02587689	Phase 1/2	MUC1	(155)
NCT04430595	Phase 1/2	HER2, GD2 and CD44v6	(156)
NCT02915445	Phase 1	EpCAM	(157)
NCT03635632	Phase 1	GD2	(158)

InternationalJournal ofOncology

Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review)

This article is mentioned in:

Abstract

1. Introduction

2. Requirements for CAR T-cell development

3. Characterisation of the CAR domains

Ligand-binding domain

Figure 1

Spacer domain

Transmembrane domain

Signalling domain

4. Generations of CARs

First generation

Figure 2

Second generation

Third generation

Fourth generation

Fifth generation

5. Mechanism of lysing the tumour cells

Figure 3

6. Preclinical experiments on mouse models

Table I

Table I

7. Malignancy-specific CAR T-cell clinical trials and BC CAR T-cell clinical studies

Table II

Table II

Table III

Table III

8. FDA-approved therapies

Figure 4

9. Contemporary advances in breast carcinoma CAR T cell therapy

10. Limitations

CRS

On/off-target carcinogen recognition

Anaphylaxis

Toxicities in BCa and TNBC

11. Conclusions and future perspectives

Availability of data and materials

Authors' contributions

Ethics approval and consent to participate

Patient consent for publication

Competing interests

Acknowledgments

Funding

References

Related Articles

International
Journal of
Oncology